Aileron Therapeutics Inc
NASDAQ:ALRN
Income Statement
Earnings Waterfall
Aileron Therapeutics Inc
Income Statement
Aileron Therapeutics Inc
| Jun-2016 | Sep-2016 | Dec-2016 | Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||||||||||||||||
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | |||||||||||||||||||||||||||||||||||
| Operating Expenses |
(16)
|
(17)
|
(18)
|
(19)
|
(18)
|
(20)
|
(23)
|
(26)
|
(31)
|
(32)
|
(32)
|
(31)
|
(29)
|
(30)
|
(30)
|
(30)
|
(27)
|
(24)
|
(21)
|
(21)
|
(22)
|
(24)
|
(27)
|
(28)
|
(30)
|
(30)
|
(28)
|
(23)
|
(17)
|
(13)
|
(15)
|
(19)
|
(26)
|
(30)
|
|
| Selling, General & Administrative |
(8)
|
(8)
|
(8)
|
(8)
|
(6)
|
(7)
|
(9)
|
(10)
|
(13)
|
(13)
|
(13)
|
(14)
|
(12)
|
(13)
|
(12)
|
(12)
|
(11)
|
(10)
|
(9)
|
(9)
|
(9)
|
(10)
|
(10)
|
(9)
|
(10)
|
(10)
|
(10)
|
(9)
|
(9)
|
(8)
|
(11)
|
(13)
|
(16)
|
(17)
|
|
| Research & Development |
(8)
|
(9)
|
(10)
|
(11)
|
(12)
|
(13)
|
(14)
|
(16)
|
(18)
|
(19)
|
(18)
|
(18)
|
(17)
|
(17)
|
(18)
|
(18)
|
(16)
|
(14)
|
(11)
|
(11)
|
(13)
|
(14)
|
(17)
|
(19)
|
(20)
|
(20)
|
(18)
|
(14)
|
(9)
|
(4)
|
(4)
|
(6)
|
(9)
|
(13)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Operating Income |
(16)
N/A
|
(17)
-6%
|
(18)
-7%
|
(19)
-4%
|
(18)
+3%
|
(20)
-12%
|
(23)
-13%
|
(26)
-14%
|
(31)
-18%
|
(32)
-3%
|
(32)
+0%
|
(31)
+1%
|
(29)
+7%
|
(30)
-1%
|
(30)
-1%
|
(30)
+1%
|
(27)
+10%
|
(24)
+11%
|
(21)
+13%
|
(21)
-1%
|
(22)
-8%
|
(24)
-8%
|
(27)
-11%
|
(28)
-5%
|
(30)
-7%
|
(30)
+1%
|
(28)
+7%
|
(23)
+16%
|
(17)
+26%
|
(13)
+26%
|
(15)
-20%
|
(19)
-21%
|
(26)
-38%
|
(30)
-16%
|
|
| Pre-Tax Income | |||||||||||||||||||||||||||||||||||
| Interest Income Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
(1)
|
(1)
|
(1)
|
0
|
0
|
0
|
|
| Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Pre-Tax Income |
(16)
N/A
|
(17)
-6%
|
(18)
-7%
|
(19)
-3%
|
(18)
+3%
|
(20)
-11%
|
(23)
-12%
|
(26)
-13%
|
(30)
-18%
|
(31)
-4%
|
(32)
-1%
|
(31)
+1%
|
(29)
+7%
|
(29)
-1%
|
(29)
-1%
|
(29)
+2%
|
(26)
+10%
|
(23)
+10%
|
(21)
+10%
|
(21)
-1%
|
(23)
-6%
|
(24)
-7%
|
(26)
-7%
|
(28)
-6%
|
(30)
-8%
|
(30)
+1%
|
(27)
+8%
|
(24)
+13%
|
(17)
+26%
|
(13)
+26%
|
(16)
-21%
|
(18)
-15%
|
(25)
-40%
|
(29)
-16%
|
|
| Net Income | |||||||||||||||||||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(16)
|
(17)
|
(18)
|
(19)
|
(18)
|
(20)
|
(23)
|
(26)
|
(30)
|
(31)
|
(32)
|
(31)
|
(29)
|
(29)
|
(29)
|
(29)
|
(26)
|
(23)
|
(21)
|
(21)
|
(23)
|
(24)
|
(26)
|
(28)
|
(30)
|
(30)
|
(27)
|
(24)
|
(17)
|
(13)
|
(16)
|
(18)
|
(25)
|
(29)
|
|
| Net Income (Common) |
(16)
N/A
|
(17)
-6%
|
(18)
-7%
|
(19)
-3%
|
(18)
+3%
|
(20)
-11%
|
(23)
-12%
|
(26)
-13%
|
(30)
-18%
|
(31)
-4%
|
(32)
-1%
|
(31)
+1%
|
(29)
+7%
|
(29)
-1%
|
(29)
-1%
|
(29)
+2%
|
(26)
+10%
|
(23)
+10%
|
(21)
+10%
|
(21)
-1%
|
(23)
-6%
|
(24)
-7%
|
(26)
-7%
|
(28)
-6%
|
(30)
-8%
|
(30)
+1%
|
(27)
+8%
|
(24)
+13%
|
(17)
+26%
|
(13)
+26%
|
(16)
-21%
|
(18)
-15%
|
(25)
-40%
|
(29)
-16%
|
|
| EPS (Diluted) |
-21.67
N/A
|
-23.05
-6%
|
-24.59
-7%
|
-25.44
-3%
|
-24.62
+3%
|
-27.35
-11%
|
-30.6
-12%
|
-34.67
-13%
|
-40.82
-18%
|
-42.4
-4%
|
-42.63
-1%
|
-42.1
+1%
|
-20.89
+50%
|
-20.97
0%
|
-23.87
-14%
|
-20.79
+13%
|
-16.75
+19%
|
-11.87
+29%
|
-12.16
-2%
|
-5.12
+58%
|
-5.01
+2%
|
-5.37
-7%
|
-5.89
-10%
|
-6.1
-4%
|
-6.6
-8%
|
-6.52
+1%
|
-6.02
+8%
|
-5.21
+13%
|
-3.84
+26%
|
-2.84
+26%
|
-3.42
-20%
|
-2.17
+37%
|
-1.26
+42%
|
-1.34
-6%
|
|